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ARTICLE

Activation of mGluR2/3 receptors in the
ventro-rostral prefrontal cortex reverses
sensorimotor gating deﬁcits induced by
systemic NMDA receptor antagonists

Anatomy & Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, N6A 5C1, Canada

Abstract
Prepulse inhibition (PPI) of acoustic startle is an operational measure of sensorimotor gating, which is disrupted
in schizophrenia. NMDA receptor (NMDAR) antagonist induced PPI disruption has become an important
pharmacological model for schizophrenia; however, knowledge of the underlying mechanism remains incomplete. This study examines the role of NMDAR in the caudal pontine reticular nucleus (PnC) and the medial
prefrontal cortex (mPFC) in NMDARs antagonist induced PPI deﬁcits, as well as the NMDA receptor subtypes
involved. We administered the NMDA antagonist MK-801 locally into the caudal pontine reticular formation
(PnC), where the PPI mediating pathway converges with the primary startle pathway, and into the mPFC
prior to behavioural testing. PnC microinjections had no effect on startle and PPI, whereas injections into the
ventro-rostral part, but not into the dorso-caudal part of the mPFC, disrupted PPI. These effects could be
mimicked by local injection of the NR2B subunit speciﬁc antagonist ifenprodil, whereas co-application of
MK-801 and the mGluR2/3 agonist LY354740 had no effect on PPI. Moreover, PPI disruptions by systemically
administered MK-801 could be reversed by local injections of LY354740 into the ventro-rostral mPFC, but not
into the dorso-caudal mPFC. Our results indicate that NR2B subunit containing NMDARs in a speciﬁc subregion
of the mPFC play a major role in PPI disruptions by systemic NMDAR antagonism. Our results further
support the hypothesis that glutamate hyper-function in the mPFC is a main mechanism involved in sensory
gating deﬁcits induced by systemic MK-801, supporting the notion that this is an important mechanism in
schizophrenia pathology.
Received 15 April 2013; Reviewed 21 May 2013; Revised 2 August 2013; Accepted 5 August 2013;
First published online 26 September 2013
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Introduction
Sensorimotor gating is a pre-attentive mechanism that
can be measured as prepulse inhibition (PPI) of acoustic
startle responses in humans and in animal models
(Geyer and Braff, 1987; Braff and Geyer, 1990; Braff
et al., 1992). It describes the inhibition of a startle response
to a sudden loud noise stimulus by a preceding prepulse.
This prepulse can be any sensory stimulus that does not
elicit a startle reaction itself; often a low volume acoustic
stimulus is used. Sensorimotor gating deﬁcits, and hence
disruption of PPI, are hallmarks of schizophrenia and can
also be observed in other neurological disorders (Geyer
and Braff, 1987; Swerdlow et al., 1995, 2000). In animal
models, the administration of dopamine agonists induces
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PPI deﬁcits (Mansbach et al., 1988), which are reversed by
antipsychotic drugs. In people with schizophrenia, however, antipsychotics often do not, or only partly, reverse
PPI deﬁcits. Since PPI deﬁcits are strongly associated
with other cognitive disruptions (Swerdlow et al., 2006;
Singer et al., 2013), drug targets other than the dopaminergic system are sought in order to address this group of
schizophrenia symptoms. The most promising alternative
model is the glutamatergic schizophrenia model. This
model is based on the observation that the administration
of non-competitive NMDAR antagonists such as phencyclidine (PCP) induces not only the positive, but also the
negative and cognitive symptoms of schizophrenia in
humans (Javitt, 1987; Javitt and Zukin, 1991; Krystal
et al., 1994) and PPI deﬁcits in rats (Mansbach and Geyer,
1991; Moghaddam and Bolinao, 1994). It is thought that
NMDAR antagonism may simulate NMDAR hypofunction in the mPFC associated with schizophrenia, thus
producing similar effects on behavioural and cognitive
processes (Moghaddam and Javitt, 2012; see also
O’Donnell, 2012). Further investigations have revealed evidence that NMDAR hypo-function results in an increased
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Method
Animals
Sprague–Dawley rats obtained from Charles River®
(Canada) were used for all experiments. Rats weighed
about 250–300 g at the time of surgery, and about
300–350 g at the time of testing. Animals were group
housed until surgery in clear plastic caging with ad libitum
access to rat chow and water, and individually housed
following surgery to prevent injury to the animals and
damage to the implants. Animals were kept on a
12:12 h light–dark cycle with transitions at 07.00 hours
and 19.00 hours, in a temperature controlled room kept
at 23 °C. All animal procedures were approved by the
University of Western Ontario Animal Use Committee,
and complied with the ethical guidelines of the
Canadian Council on Animal Care involving vertebrate
animals in research. All efforts were made to minimize animal suffering and to reduce the number of animals used.
Stereotaxic surgery
Two to ﬁve days following arrival, rats underwent
surgery to implant bilateral chronic indwelling cannulae
(28 gauge, PlasticsOne, USA) targeted bilaterally to either
the PnC or mPFC. Animals were anesthetized via inhalation of 2% vapourized isoﬂurane (Forane) and 98% oxygen delivered to the nose cone attached to the stereotaxic
apparatus (Stoelting, USA). They also received injections
of 0.05 mg/kg buprenorphine and 2.5 mg/kg ketoprofen

for analgesia, and an injection of 5 ml/kg 0.9% sterile
saline to ensure proper hydration during recovery.
Cannula coordinates were as follows: mPFC (DV: −3.2
to −3.7 mm from skull surface; ML: ± 0.6 mm, from midline; RC: +2.7 to +3.2 mm from bregma) and PnC
(DV: −8.50 mm, from skull surface; ML: ± 2.50 mm, from
midline; RC: −2.00 mm, from lambda; cannulae were laterally angled at 10° in order to avoid severing the choroid
plexus). The cannulae were anchored to the skull using
four stainless steel bone screws and dental cement, and
the wound was closed using silk suture. Stainless steel
stylets (PlasticsOne) were inserted to keep the cannulae
free of obstructions. After surgery, animals were allowed
to heal for 4–7 d before handling.
Initial handling and exposure to behavioural paradigm
Handling was done daily for 1–2 min per rat to replace
stylets, and habituate the subjects to handling. The rats
were handled and tickled to increase their afﬁnity for
their handlers (Burgdorf & Panksepp, 2001). Rats were
handled for three consecutive days before any injection
to ensure habituation to being handled by the experimenter. All subjects were also placed in the startle
boxes on the day before testing for one exposure to the behavioural paradigm and conﬁnement in the startle boxes.
Drugs
The general non-competitive NMDAR antagonist MK-801
(Sigma, USA), and the NR2B subtype speciﬁc, noncompetitive NMDA antagonist ifenprodil (Sigma) were
dissolved in 0.9% saline. The mGluR2/3 agonist LY
354740 (Tocris, UK) was dissolved in 0.9% saline with
1 eq. NaOH. All drugs were maintained at −18 °C following dissolution. MK-801 was administered systemically
(0.01, 0.1, 1.0 mg/kg, i.p.) and intracranially (i.c.) (5,
50 mM). Ifenprodil was administered i.c. (100, 1 mM). LY
354740 was administered i.c. (500 μM). All doses used
are within the range of well-established doses in the
literature (systemic MK-801: Geyer et al., 2001; Bortolato
et al., 2004; Schwabe and Koch, 2004; MK-801 microinfusion: Bakshi and Geyer, 1998; Bakshi & Geyer 1999;
Zhang et al., 2000; Figueroa-Guzmán et al., 2006; ifenprodil microinfusion: Ma et al., 2007; Day et al., 2011;
Blair et al., 2005; LY 354740 microinfusion: Jackson &
Moghaddam 2001; Mela et al., 2006). In general, doses
for microinfusions were 100–1000 times the minimal
effective dose in order to account for dilution by the extracellular ﬂuid.
Intracranial drug infusion
Each animal got one saline injection and either one or two
drug injections, with at least 5 d in between injections.
Order of saline and drug injections was pseudorandomized. Injections of 0.5 μl of saline or drug per site were
done using 5 μl Hamilton micro-syringes mounted on a
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glutamate release in the medial prefrontal cortex (mPFC)
and excitation of non-NMDARs, and that this effect can
be reversed by inhibition of glutamate release, e.g. by
the activation of mGluR2/3 receptors (Olney and Farber,
1995; Moghaddam et al., 1997; Jackson et al., 2004;
Homayoun and Moghaddam, 2007). The particular importance of the mPFC in the glutamatergic schizophrenia
model has also been implicated through a study by
Schwabe and Koch (2004), showing that NMDAR antagonism fails to induce PPI deﬁcits in mPFC lesioned animals.
NMDARs, however, are abundantly expressed in the
brain, including in areas directly implicated in mediating
startle and PPI. Startle mediating neurons in the pontine
reticular formation receive glutamatergic sensory and
modulatory input that activates different glutamate
receptors, including NMDARs (Weber et al., 2002;
Schmid et al., 2010). Here, we addressed the hypothesis
that systemic NMDAR antagonists exert their main effects
on sensorimotor gating through NMDAR inhibition in the
mPFC, rather than on neuronal pathways directly involved
in prepulse inhibition of startle. We further tested whether
NR2B subunit containing NMDARs are involved, and
whether the inhibition of glutamate release in the mPFC
through the local administration of the mGluR2/3 agonist
LY354740 can reverse PPI deﬁcits induced by systemically
administered MK-801.
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motorized pump (World Precision Instruments, USA).
Injections occurred over a period of 4 min, and the injectors were left in place for an additional 1–2 min in order
to ensure that the drug dispersed and did not ﬂow back
within the cannulae. Following injections, stylets were
sterilized and replaced, and animals were returned to
their home cages.

Behavioural testing was done in startle boxes (Med
Associates, USA) using the Startle reﬂex 5.95 software
(Med Associates). The behavioural testing paradigm consisted of the following phases: the acclimation phase,
a habituation phase (block 1), and PPI measurement
(block 2, see also Valsamis and Schmid, 2011). During
the acclimation phase animals were exposed to the
chambers and white background noise (65 dB) for
3 min. During block 1, 30 startle trials (105 dB white
noise, 20 ms duration) were delivered at 20 s intervals.
Block 2 consisted of the presentation of seven different
trials presented 10 times each in a pseudo-randomized
order and at 30 s intervals: 10 pulse-alone trials and 10
of each of six different prepulse–pulse trial types
with three different interstimulus intervals (12, 50 and
100 ms) and two different prepulse sound pressure levels
(75 and 85 dB). ‘Pulse-alone’ trials consisted of startle
stimulus only presentation, while ‘prepulse–pulse’ trials
consisted of the presentation of a weaker non-startling
prepulse (white noise, 4 ms duration, volume as indicated) at a speciﬁc interstimulus interval (ISI) before the
startling stimulus. All animals underwent the entire protocol once before injections started (pretest). In some rare
cases, animals showed extremely low PPI, potentially
caused by the preceding surgery (PPI of less than 35%
across multiple ISIs) and these animals were excluded
from further experiments.
Data analysis
Data was analysed using Microsoft Excel (Version
14.0.6129.5000, Microsoft, USA) and SPSS (v.20.0.0, IBM,
USA). All trials were controlled for potential startle
responses to the prepulse. Although the startle threshold
for some animals is below 85 dB according to the
input/output function, animals did not startle to the prepulses, probably because of their shorter duration of the
prepulse (4 ms vs. 20 ms in the I/O function). The startle
amplitude (peak-to-peak) to the 105 dB pulse was analysed for each trial. PPI was calculated from block 2
data using the following formula:
%prepulse inhibition = [1 − (prepulse − pulse trial
amplitubes)/(pulse alone trial
amplitude)] × 100
Drug effects on PPI were calculated by averaging over the
10 trials of a given stimulus condition. Drug effects on

Histology
After completion of testing, animals were euthanized.
Intracranial injection of 0.2 μl stock thionine solution
was performed post-mortem in order to label injector
tips placements, and the brains were removed and ﬁxed
in 10% formalin. Brains were then immersed in 10%
formalin +15% sucrose for cryoprotection and sectioned,
using a freezing microtome, at a thickness of 50 μm.
Slices were mounted and stained with thionine, cover
slipped and examined for cannula placement. Cannula
placement conﬁrmation was performed using a rat
brain atlas (Paxinos and Watson, 2005).

Results
In order to test the effects of drugs on PPI, we used
two different levels of prepulses, 75 and 85 dB, and
three different interstimulus intervals (ISI) between prepulse and startle pulse, 12, 50 and 100 ms. The higher prepulse intensity leads to maximum PPI at an ISI of 50 ms,
however, PPI induced by lower prepulse intensities is
often more sensitive to disruptions. Furthermore, it is

Downloaded from https://academic.oup.com/ijnp/article-abstract/17/2/303/756763 by University of Western Ontario user on 21 October 2019

Behavioural testing

baseline startle amplitude were calculated by averaging
the ﬁrst 20 startle responses in block 1.
In very rare cases, the baseline startle response in an
animal was very low and close to the noise level. In this
case no prepulse inhibition can be observed, and our
methods lead to prepulse inhibition values of below
zero (indicating sensitization rather than prepulse inhibition). The respective data points were excluded
from analysis. Drug effects were assessed with repeated
measurement ANOVAs with drug, prepulse level and
inter-stimulus interval as within subject factors.
However, for the intracranial injections of MK-801 (see
Fig. 2) and ifenprodil (see Fig. 4) the number of subjects
with a complete data set with all drug concentration is
relatively low. To avoid losing the complete data sets of
the respective animals we used a mixed model approach.
We ran a general linear model (PROC GLM) with all
interactions usually seen in a repeated measure ANOVA
and with restricted maximum likelihood as an estimate.
Degrees of freedom were calculated with the Kenward–
Rogers method. Additional to the within-subject effects
(drug, prepulse level and interstimulus interval), the
injection site (dorso-caudal and ventro-rostral) was considered as a between-subject effect for these two data
sets. Statistics were run in consultation with the LW
Stitt Statistical Services (Canada).
Group comparisons and post-hoc tests were done using
the Bonferroni correction to account for repeated testing.
Differences were considered statistically signiﬁcant
when p-values were smaller than 0.05. In the ﬁgures
data is presented as means (±S.E.M. between animals).
Signiﬁcant differences in means are shown with * for
p < 0.05.
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(b): Local MK-801 in PnC
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Fig. 1. Systemic MK801, but not local microinfusion into the PnC, disrupt PPI. (a) Systemic MK-801 administration
dose-dependently disrupts PPI at both 75 and 85 dB prepulse amplitudes (n = 7). Systemic MK-801 also signiﬁcantly increases
baseline startle amplitude at the 0.1 mg/kg dose (right panel). Startle amplitudes are displayed in arbitrary units. (b) Microinfusion
of MK-801 into the PnC had no signiﬁcant impact on PPI at 75 or 85 dB prepulse levels (n = 8). Local microinfusion into the PnC
had no signiﬁcant effect on baseline startle (right panel).

hypothesized that PPI is mediated by different neurotransmitters and receptors at different ISIs (Jones and
Shannon, 2000; Yeomans et al., 2010), and is, therefore,
differentially susceptible to pharmacological disruptions
(see also Mansbach and Geyer, 1991).
Systemic NMDAR antagonists
First, we aimed to reproduce the systemic effect of the
NMDAR antagonist MK-801on PPI.
We injected seven animals with three different
doses of MK-801 (0.01, 0.1, 1.0 mg/kg), and saline as a
control in a pseudorandomized order and at least 5 d
apart (Fig. 1(a)). As expected, the repeated measurement
ANOVA (drug × level of prepulse × ISI) yielded main
effects for the level (F1,6 = 294.949, p < 0.001) and the ISI
(F2,12 = 6.727, p = 0.011), as well as a level × ISI interaction

(F2,12 = 7.386, p = 0.008). More importantly, it also
conﬁrmed the drug effect (F3,18 = 29.276, p < 0.001).
Pairwise comparison (Bonferroni corrected) revealed
that both the 0.1 and 1.0 mg/kg doses signiﬁcantly disrupted PPI, while no signiﬁcant disruption was observed
at the 0.01 mg/kg dose. MK-801 also signiﬁcantly
increased baseline startle amplitude (repeated measurement ANOVA, F3,18 = 6.491, p = 0.004). But pairwise
comparison showed that only the 0.1 mg/kg dose signiﬁcantly increased baseline startle amplitude.
In the following experiments we injected MK-801
locally into two different brain regions implicated in mediating/modulating PPI: the PnC, where the startle mediating neurons receive sensory glutamatergic input and
modulatory input from different brain regions; and the
mPFC which has been previously implicated as an important structure in NMDAR antagonist induced PPI deﬁcits.
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(b): Ventro-rostral mPFC
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Fig. 2. MK-801 microinfusions into the ventral mPFC disrupts PPI. (a) Prepulse inhibition levels after intracranial (i.c.)
administration of saline, and two different doses of MK-801, into the dorsal-third and most caudal areas of the mPFC. No
signiﬁcant effect on PPI is observed. Prepulse inhibition values are shown with 75 dB (saline: n = 14; 5 mM MK-801: n = 14; 50 mM
MK-801: n = 8) and 85 dB prepulse levels (saline: n = 8; 5 mM MK-801: n = 8; 50 mM MK-801: n = 8). No signiﬁcant effect on baseline
startle amplitude was observed after i.c. mircoinfusions of MK-801 into the dorso-caudal mPFC (right panel). (b) Prepulse inhibition
levels after i.c. administration of MK-801 to the ventral two thirds and most caudal areas of the mPFC are disrupted at the 75 dB
(saline: n = 15; 5 mM MK-801: n = 15; 50 mM MK-801: n = 15) and the 85 dB prepulse (saline: n = 5; 5 mM MK-801: n = 5; 50 mM MK-801:
n = 5). Baseline startle was not affected (right panel).

Local injections into the PnC

Local injections into the mPFC

Eight animals received 5 and 50 mM local MK-801 injections into the PnC, as well as a local saline injection as
its own control (each 0.5 μl/side), in a pseudorandomized
order and at least 5 d apart (Fig. 1(b)). The repeated
measurement ANOVA (drug × level of prepulse × ISI)
revealed no drug effect (F2,14 = 1.3030, p = 0.382), nor any
interaction of level and ISI with the drug. However, the
expected main effects for the prepulse level (F1,7 = 19.202,
p = 0.003) and the ISI (F2,14 = 8.000, p = 0.005) can still be
observed. MK-801 injections into the PnC also had no
effect on the baseline startle amplitudes (repeated
measurement ANOVA, F2,14 = 1.140, p = 0.348). Please see
supplementary material, Fig. S1 for localizations of PnC
cannulae.

All animals received one (5 mM, n = 16) or two (5 and
50 mM, n = 13) local MK-801 injections and a local saline
injection as control in a pseudorandomized order and at
least 5 d apart (Fig. 2). Local injections of MK-801 into
the mPFC initially revealed very inconsistent effects on
PPI: in a ﬁrst batch of animals PPI was clearly disrupted,
whereas in a second cohort PPI was unaffected or even
enhanced. Upon further histological analysis of injection
sites, a clear image emerged: local injections of MK-801
in the rostral and ventral region of the mPFC led to a disruption of PPI whereas MK-801 injections into the dorsal
and caudal parts of the mPFC at the second cohort had no
effect, or enhanced PPI. We therefore targeted either the
ventro-rostral or the dorso-caudal portion of the mPFC

Downloaded from https://academic.oup.com/ijnp/article-abstract/17/2/303/756763 by University of Western Ontario user on 21 October 2019

Prepulse inhibition (%)

mPFC MK-801 50mM

80%

308

B. Valsamis et al.

Rostral

Fig. 3. Localizations of the mPFC microinjections. Coronal
sections indicating the location of injector tips in the mPFC,
and the local effect of MK-801 injection on PPI at each site.
Each asterisk and circle represents injector tip placement in a
different animal (animals received bilateral cannulation and
injections). Asterisks indicate cannula localizations that lead to
a decrease in PPI after injections of MK-801, black circles
indicate an increase in PPI, unﬁlled circles indicate no effect on
PPI. Coronal sections shown here are 0.24 mm apart, and the
rostral-most section is 3.72 mm anterior to bregma. Atlas
illustrations adapted from the atlas of Paxinos and Watson
(2005).

in subsequent experiments by adjusting the stereotaxic
parameters by 0.5 mm in the respective dimension.
The mixed model (injection site × drug × prepulse
level × ISI, BIC=−140.3) on PPI in these animals conﬁrmed
this phenomenon. There was a signiﬁcant main effect
for the injected drug (F2,273 = 17.68, p < 0.001), as well as
an interaction between the injection site and the drug
(F2,273 = 8.99, p < 0.001). Post-hoc analyses indicate that
both doses of MK-801 signiﬁcantly disrupted PPI (5 mM:
p = 0.006 and 50 mM: p < 0.001). However, follow-up analyses for the injection sites at the different prepulse levels
showed that injections of MK-801 located approximately
within the dorsal third of the mPFC, and within the caudal most 0.5 mm of the rostro-caudal extent of the mPFC,
had no effect on PPI with either 75 db (F2,99 = 1.441,

NMDA antagonist combined with LY354740
It has previously been shown that activation of mGluR2/3
in the mPFC inhibits glutamate release and thereby
opposes the effect of NMDAR antagonists that are
assumed to increase glutamate release in the mPFC (see
Introduction). We therefore tested whether the injection
of LY 354740 into the ventro-rostral mPFC (10 mM, 0.5 μl/
side) reverses PPI disruption caused by MK-801 (0.1 mg/
kg) (Fig. 5). Ten animals were tested on three different
days with a recovery period of at least 5 d in between.
They have been tested after the following treatments:
(1) systemic and local saline, (2) systemic MK-801 and
local saline and (3) systemic MK-801 and local LY 354740.
The order of the treatments was pseudorandomized.
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Caudal

p = 0.224, nSaline = 14, nMK-801 5 mM = 14, nMK-801 50 mM = 8)
or 85 dB prepulse amplitudes (F2,63 = 0.149, p = 0.862,
nSaline = 8, nMK-801 5 mM = 8, nMK-801 50 mM = 8). In contrast,
injections of MK-801 placed within the ventral two-thirds
of the mPFC, over most of the rostro-caudal extent of
the mPFC except the caudal-most area, signiﬁcantly disrupted PPI at both, the 75 dB (F2,96 = 18.494, p < 0.001,
nSaline = 15, nMK-801 5 mM = 15, nMK-801 50 mM = 15) and the
85 dB prepulse amplitude (F2,36 = 4.790, p = 0.014, nSaline = 5,
nMK-801 5 mM = 5, nMK-801 50 mM = 5) at all ISIs.
There was no signiﬁcant effect of MK-801 on
baseline startle (two-way ANOVA, injection site × drug,
drug: F2,65 = 2.532, p = 0.087, injections site: F1,65 = 2.706,
p = 0.105, interaction: F2,65 = 0.152, p = 0.859). The exact
placements of the injector tips of both groups are
displayed in Fig. 3.
In order to evaluate the possible involvement of the
NR2B subunit in this effect, we repeated the same microinjections with the non-competitive NMDAR subunit
NR2B antagonist ifenprodil (Fig. 4). Animals received
either one (1 mM, n = 15) or two (100 and 1 mM, n = 17)
injections of ifenprodil into the mPFC. Those injections
did show a similar relationship between cannula placement and drug effect as the MK-801 injections. Though
the mixed model analysis (injection site × drug × prepulse
level × ISI, BIC=−241.3) on PPI in these animals did not
report a signiﬁcant effect for the injection site (F1,31.2 =
2.01, p = 0.167), or the drug (F2,322 = 2.58, p = 0.077)
alone, it revealed an interaction between both (F2,322 =
4.37, p = 0.013), as well as between the drug and the
prepulse level (F2,322 = 5.01, p = 0.007).The follow-up
analyses (drug × ISI) for the injection sites at the different
prepulse levels depicted a signiﬁcant effect of the ifenprodil only for the 75 dB prepulse level in the ventro-rostral
injections (F2,90 = 5.750, p = 0.004, nSaline = 15, nIfen100 μM = 5,
nIfen1 mM = 14) with only the high dose signiﬁcantly impairing PPI (100 μM: p = 0.999, 1 mM: p = 0.008). The baseline
startle was not signiﬁcantly affected by the ifenprodil
injections (two-way ANOVA, injection site × drug,
drug: F2,75 = 0.562, p = 0.572, injections site: F1,75 = 1.705,
p = 0.196, interaction: F2,75 = 1.335, p = 0.269).
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Fig. 4. Microinfusions of ifenprodil into the ventral mPFC disrupts PPI. (a) Prepulse inhibition levels after intracranial (I.C.)
administration of the NR2B speciﬁc NMDA receptor antagonist ifenprodil into the dorsal-third and most caudal areas of the mPFC.
Rats received bilateral i.c. injections of 0.9% saline (control, 0.5 μl/side) and ifenprodil (100 and 1 mM, 0.5 μl/side). Prepulse inhibition
at 75 dB (saline: n = 17; 100 μM ifenprodil: n = 12; 1 mM ifenprodil: n = 17) and 85 dB prepulse levels (saline: n = 12; 100 μM ifenprodil:
n = 12; 1 mM ifenprodil, n = 12) was not signiﬁcantly altered. Baseline startle amplitudes were also not affected (right panel).
(b) Prepulse inhibition levels after i.c. administration of ifenprodil to the ventral two thirds and most caudal areas of the mPFC are
disrupted. No effect on baseline startle amplitude was observed (right panel). PPI was disrupted at the 75 dB prepulse level
(saline: n = 15; 100 μM ifenprodil: n = 4; 1 mM ifenprodil: n = 14), but not the 85 dB prepulse level (saline: n = 5; 100 μM ifenprodil: n = 5;
1 mM ifenprodil: n = 5).

A repeated measurement ANOVA (drug × prepulse
level × ISI) reported a signiﬁcant drug effect (F2,18 =
31.645, p < 0.001), as well as a drug × level interaction
(F2,18 = 3.770, p = 0.043) next to the expected level and
ISI effect. Pairwise comparison conﬁrmed previously
described effect off MK-801 (p < 0.001, compare Fig. 1(a)),
but also showed that local LY 354740 injections recovered
PPI (p = 0.008). However the local LY 354740 injections
are still signiﬁcantly different to the saline/saline controls
(p = 0.005), indicating only a partial recovery. Follow-up
ANOVAs for the two different prepulse levels showed
that this recovery is only signiﬁcant at the 85 dB prepulse,
but there is also a trend for a recovery at the 75 dB

prepulse. The baseline startle amplitude was not affected
by the drugs (repeated measurement ANOVA, F2,18 =
1.659, p = 0.218).
Discussion
Our results conﬁrm a robust disruption of PPI by systemic administration of MK-801, and an increase of baseline startle, according to previous studies (Mansbach and
Geyer, 1989; Chaperon et al., 2003). Interestingly, local
application of MK-801 into the PnC did not affect PPI
or baseline startle, indicating that NMDARs expressed
in the PnC play only a minor role in these behavioural
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Fig. 5. Local microinfusion of LY354740 reverses systemic MK-801 effects. Prepulse inhibition levels after combined systemic
administration of MK-801 (0.1 mg/kg) and local microinjection of either saline or LY354740 (500 μM) into the ventral mPFC (n = 10).
Local injections of LY354740 signiﬁcantly reversed the effect of systemic MK-801 at the 85 dB prepulse level. The baseline startle
amplitude was not affected by the injections (right panel).

responses. In contrast, local MK-801 application in the
mPFC disrupted PPI, at least at the 75 dB prepulse levels,
indicating a major role of NMDARs in the mPFC in mediating the PPI disruptions induced by systemic NMDAR
antagonists. The baseline startle response was not
affected. The effect of local MK-801 application on PPI
was markedly smaller than that of systemic MK-801
application, and limited to the more vulnerable 75 dB prepulse paradigm. This could be due to the fact that local
drug applications might not be effective over the entire
mPFC area important for PPI modulation, due to the
increasing dilution of the drug as it diffuses away from
the injection site. Alternatively, brain areas other than
the mPFC might contribute to the systemic effect of
MK-801, and these might also be responsible for the
MK-801 effect on baseline startle responses. Local application of LY 354740 into the mPFC paired with systemic
MK-801 application rescued PPI only partially. This
again, could be due to either spatially limited effects of
local drug injections into the mPFC, or the additional
contribution of NMDARs outside the mPFC. A strong
argument for the ﬁrst explanation lies in the fact that
systemically induced PPI deﬁcits could be eliminated by
prior lesions to the mPFC (Schwabe and Koch, 2004). In
any case, NMDARs in the mPFC play a major role in
these systemically induced PPI disruptions, and our
data indicate that this NMDAR population includes
NR2B subunit containing receptors, since local MK-801
effects could be mimicked by the local injection of
ifenprodil.
MK-801 microinfusion to the mPFC has been previously shown to cause only trend-level inhibition of
PPI (Bakshi and Geyer, 1998). Our results showed a
relationship between injection location within the mPFC
and the effect of NMDA antagonism. Our injections

were targeted to the prelimbic area of the mPFC. Only
injections to the ventral two-thirds of the prelimbic area
were effective in disrupting PPI. Injections to the dorsal
third, and the most caudal 0.5 mm of the mPFC had
no effect on PPI. This division between the dorsal and
ventral injection sites with respect to the effect of
NMDA antagonism within the prelimbic cortex of rats
may explain the inconclusive effect of local NMDA antagonism found by others.
Our results support the notion that there exists a division of the medial prefrontal cortex into a dorsal and a
ventral component, and only NMDARs in the ventral
portion appear to play a role in PPI modulation. On the
basis of functional and anatomical criteria it has been previously suggested that there exists a dorsal compartment
within the medial prefrontal cortex encompassing the
FR2, dorsal anterior cingulate areas, and the dorsal part
of the prelimbic area; and a ventral compartment that
includes the ventral prelimbic, infralimbic and medial
orbital areas (Gisquet-Verrier et al., 2000, for review
see Heidbreder and Groenewegen, 2003; Rogazzino,
2007). This distinction is associated with differences in
cytoarchitecture, connectivity patterns, neurochemistry
and immediate early genes expression. Functionally, it
appears that the dorsal regions are involved with generating rules associated with temporal ordering and motor
sequencing of behaviour (see reviews Gisquet-Verrier
et al., 2000; Kesner, 2000), or behavioural ﬂexibility
when conditions require a shift in strategy (Uylings
et al., 2003), whereas the ventral regions are involved in
attentional and response selection functions as well as
visual working memory (e.g. Granon and Poucet, 2000).
Our results support a functional distinction between ventral and dorsal mPFC, and suggest that only the ventral
part of the mPFC modulates PPI, which is interesting in
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Conclusion
In summary, this study conﬁrms that NMDARs receptors
in the mPFC, but not within the brainstem structures of
the primary startle pathway, play an important role
in modulating sensorimotor gating. The results further
implicate that NR2B subunit containing receptors at
least partially mediate this effect. Most importantly,
only the inhibition of NMDA receptors expressed in the
ventral portion of the mPFC are able to disrupt PPI,
whereas NMDA antagonism in the dorsal region had
no, or an opposite, effect. These ﬁndings emphasize the
notion that there are functional differences between the
dorsal and ventral regions of the mPFC, and more speciﬁcally between the dorsal and the ventral portions of the
prelimbic area.
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